← Research library / Support

NAD+ (Injectable): What the Evidence Actually Shows

Grade CAvailable

The short version

  • A coenzyme present in every cell, central to energy metabolism and DNA repair.
  • Levels decline with age, which is the basis for the longevity positioning.
  • Compounded injectable and IV forms are available with a prescription.
  • Human outcome evidence is thin, and much of the strongest data is for precursors rather than NAD+ itself.
  • IV infusion is frequently uncomfortable at speed. That is expected, not a reaction.

What it is

Nicotinamide adenine dinucleotide is not an exotic compound. It is a fundamental coenzyme involved in redox reactions across cellular metabolism, and in the activity of sirtuins and PARP enzymes involved in DNA repair. The observation that NAD+ levels fall with age is well established and genuinely interesting.

Where the evidence actually is

The strongest human data in this space is not for NAD+ itself but for its precursors, particularly nicotinamide riboside and nicotinamide mononucleotide, taken orally. Those trials reliably show that blood NAD+ levels can be raised.

What is much weaker is the next link: evidence that raising NAD+ produces the clinical outcomes people are seeking. Trials looking at functional endpoints have generally been small and mixed. Direct IV NAD+ has less controlled evidence than the oral precursors, not more, despite costing considerably more.

What to expect

IV NAD+ infusions commonly produce chest tightness, flushing, nausea and a general unpleasant sensation if run quickly. Slowing the infusion resolves it. This is a well known and expected effect rather than an allergic reaction, but nobody should experience it without being warned first.

What this will not do

Related

Full library · Safety and sourcing · Reconstitution calculator · Compound index

Regulatory status current as of the page date. This area is changing quickly and this page is reviewed monthly. [set review reminder]